The Psoriasis 2019

出版社： メディカルレビュー社
著者：
発行日： 2019-12-27
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784779223525
電子書籍版： 2019-12-27 （初版第1刷）
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,850 円(税込)

購入する

商品紹介

乾癬だけでなく、乾癬の併存疾患、乾癬に類似する疾患などについて最新の話題を提供。

目次

  • 表紙
  • [発刊によせて]
  • CONTENTS
  • [VISUAL View] アディポサイトカインからみた乾癬の病態
  • [ROUND TABLE DISCUSSION] 全身性炎症疾患としての乾癬とその治療
  • [プロフェッショナルが語る] 乾癬の生物学的製剤治療にかかわる今後の展開
  • [Psoriasis INTERFACE]
  • Dermatologistの立場から
  • Rheumatologistの立場から
  • [Clinical points in psoriasis] 患者との良好な関係構築からはじまる乾癬治療
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[VISUAL View] アディポサイトカインからみた乾癬の病態

P.9 掲載の参考文献
1) Kunz M, Simon JC, Saalbach A. Psoriasis : Obesity and fatty acids. Front Immunol. 2019 ; 10 : 1807.
PubMed
2) Icen M, Crowson CS, McEvoy MT, et al. Trends in incidence of adult-onset psoriasis over three decades : a population-based study. J Am Acad Dermatol. 2009 ; 60 : 394-401.
PubMed
3) Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev. 2012 ; 11 : A386-92.
PubMed
4) Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016 ; 315 : 2284-91.
PubMed
5) Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis : prospective data from the HUNT Study, Norway. Br J Dermatol. 2019 ; 180 : 94-9.
 
6) Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march' : a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011 ; 20 : 303-7.
 
7) Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, waist circumference, weight change, and risk of incident psoriasis : prospective data from the HUNT study. J Invest Dermatol. 2017 ; 137 : 2484-90.
 
8) Li WQ, Han JL, Zhang MF, Qureshi AA. Interactions between adiposity and genetic polymorphisms on the risk of psoriasis. Br J Dermatol. 2013 ; 168 : 639-42.
PubMed
9) Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017 ; 113 : 1009-23.
PubMed
10) Cecchini MG, Dominguez MG, Mocci S, et al. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development. 1994 ; 120 : 1357-72.
PubMed
11) Chang EJ, Lee SK, Song YS, et al. IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab. 2014 ; 99 : E1263-71.
PubMed
12) Ivanov S, Merlin J, Lee MKS, Murphy AJ, Guinamard RR. Biology and function of adipose tissue macrophages, dendritic cells and B cells. Atherosclerosis. 2018 ; 271 : 102-10.
 
13) Meier U, Gressner AM. Endocrine regulation of energy metabolism : review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004 ; 50 : 1511-25.
PubMed
14) Oh YJ, Lim HK, Choi JH, et al. Serum leptin and adiponectin levels in Korean patients with psoriasis. J Korean Med Sci. 2014 ; 29 : 729-34.
PubMed
15) Stjernholm T, Ommen P, Langkilde A, et al. Leptin deficiency in mice counteracts imiquimod (IMQ) -induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Exp Dermatol. 2017 ; 26 : 338-45.
PubMed
16) Kyriakou A, Patsatsi A, Sotiriadis D, et al. Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis : A Meta-Analysis of Observational Studies. Dermatology. 2017 ; 233 : 378-89.
PubMed
17) Goralski KB, Jackson AE, McKeown BT, et al. More Than an Adipokine : The Complex Roles of Chemerin Signaling in Cancer. Int J Mol Sci. 2019 ; 20. pii : E4778.
 
18) Kong Y, Zhang S, Wu R, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019 ; 18 : 171.
PubMed
19) Kanda N, Watanabe S. Leptin enhances human beta-defensin-2 production in human keratinocytes. Endocrinology. 2008 ; 149 : 5189-98.
PubMed
20) Hau CS, Kanda N, Noda S, et al. Visfatin enhances the production of cathelicidin antimicrobial peptide, human β-defensin-2, human β-defensin-3, and S100A7 in human keratinocytes and their orthologs in murine imiquimod-induced psoriatic skin. Am J Pathol. 2013 ; 182 : 1705-17.
 
21) Kanda N, Hau CS, Tada Y, et al. Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes. Endocrinology. 2011 ; 152 : 3155-64.
PubMed
22) Hau CS, Kanda N, Tada Y, et al. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J Dermatol. 2016 ; 3 : 785-94.
 

[ROUND TABLE DISCUSSION] 全身性炎症疾患としての乾癬とその治療

P.15 掲載の参考文献
1) Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019 ; 46 : 389-8.
PubMed
2) Naito R, Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan : A hospital-based case-control study. J Dermatol. 2016 ; 43 : 1406-11.
PubMed
3) Tsuruta N, Narisawa Y, Imafuku S et al. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients : Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors. J Dermatol. 2019 ; 46 : 193-8.
 
4) 門脇孝編. アディポネクチンとその受容体. 東京 : フジメディカル出版 ; 2008.
 

[プロフェッショナルが語る] 乾癬の生物学的製剤治療にかかわる今後の展開

P.19 掲載の参考文献
1) 大槻マミ太郎, 照井正, 小澤明, ほか. 乾癬におけるTNFα阻害薬の使用指針および安全対策マニュアル. 日皮会誌. 2010 ; 120 : 163-71.
 
2) 大槻マミ太郎, 照井正, 小澤明, ほか. 乾癬における生物学的製剤の使用指針および安全対策マニュアル (2011年版). 日皮会誌. 2011 ; 121 : 1561-72.
 
3) Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013 ; 40 : 683-95.
PubMed
4) 大槻マミ太郎, 佐伯秀久, 照井正, ほか. 乾癬における生物学的製剤の使用ガイダンス (2019年版). 日皮会誌. 2019 ; 129 : 1845-64.
 

[Psoriasis INTERFACE]

P.23 掲載の参考文献
1) Ohara Y, Kishimoto M, Takizawa N, et al. Prevalence and Clinical characteristics of psoriatic arthritis in Japan. J Rheumatol. 2015 ; 42 : 1439-42.
PubMed
2) Yamamoto T, Ohtsuki M, Sano S, et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol. 2016 ; 43 : 1193-6.
PubMed
3) Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis : a population-based study. Arthritis Rheum. 2009 ; 61 : 233-9.
PubMed
4) Ogdie A, Gelfand JM. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis : a review of available evidence. Curr Rheumatol Rep. 2015 ; 17 : 64.
PubMed
P.25 掲載の参考文献
1) Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target : recommendations of an international task force. Ann Rheum Dis. 2010 ; 69 : 631-7.
PubMed
2) Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010 ; 69 : 48-53.
PubMed

書評

最近チェックした商品履歴

Loading...